Neuronetics, Inc. (STIM) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Neuronetics, Inc. is a global leader in neuroscience, primarily known for the NeuroStar Advanced Therapy System for treating major depressive disorder (MDD). A significant business development in this period was the full consolidation of Greenbrook TMS Inc., acquired in December 2024, which added a network of outpatient mental health centers to the Company's operations. The Company operates as a single segment focused on TMS products and clinical services.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $31.98 million | $17.42 million |
| Gross Profit | $15.74 million | $13.09 million |
| Gross Margin | 49.2% | 75.1% |
| Net Loss | $(12.69) million | $(7.87) million |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.27) |
| Cash and Cash Equivalents | $20.22 million | $47.73 million (End of Q1 2024) |
| Long-Term Debt (Net) | $55.34 million | $55.15 million |
| Operating Cash Flow | $(16.99) million | $(12.02) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 84% year-over-year, driven primarily by the inclusion of $18.66 million in clinic revenue from the Greenbrook acquisition. This offset a decline in NeuroStar system sales (down 14%) and treatment session revenue (down 26%) due to the elimination of intercompany sales to Greenbrook.
- Gross Margin Compression: Gross margin decreased significantly from 75.1% to 49.2%. This is attributed to the lower-margin profile of the newly acquired clinic business compared to the high-margin treatment session software sales.
- Operating Expenses: Total operating expenses rose 34% to $26.75 million. General and Administrative (G&A) expenses surged 121% to $13.14 million, largely due to the consolidation of Greenbrook's G&A costs. Conversely, R&D expenses decreased 31% due to post-acquisition restructuring savings.
- Capital Raise: In February 2025, the Company completed a secondary public offering of 9.2 million shares, raising net proceeds of approximately $18.9 million.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash balances ($20.2 million) and anticipated revenues are sufficient to fund operations for at least the next 12 months. The Company has an accumulated deficit of $432.5 million.
- Debt Covenants: The Company has $60.0 million outstanding under the Perceptive Credit Facility, maturing in July 2029. The facility includes a minimum trailing revenue covenant and a minimum liquidity covenant. The Company amended the revenue covenant in March 2025 to align with its operating plan and was in compliance as of March 31, 2025.
- Outlook: The Company anticipates operating losses will continue in the near term as it invests in sales, marketing, and integration of Greenbrook. Management expects clinic revenue to increase in 2025.
- Risks: Key risks include the ability to achieve cash flow breakeven (targeted for Q3 2025), reliance on third-party payor reimbursement rates, integration challenges with Greenbrook, and potential dilution from future equity raises if liquidity needs arise.
Investor Verification Checklist
- Verify the sustainability of the 49.2% gross margin as the company integrates the lower-margin clinic business with its high-margin software sales.
- Monitor compliance with the Perceptive Facility revenue covenants, specifically the quarterly minimum trailing revenue requirements.
- Assess the trajectory of operating cash flow, which remains negative at $17.0 million for the quarter, against the $18.9 million raised in the recent equity offering.
- Review the restructuring savings realized in R&D to determine if similar efficiencies can be achieved in G&A to offset the acquisition-related cost increases.
- Confirm the reimbursement rates for clinic services from Medicare and commercial payors, as this is a primary driver of the new revenue stream.